Related Experiment Video
Updated: Jul 19, 2026
09:49
Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
Published on: December 28, 2021
Long-Term Experience With 5-alpha-Reductase Inhibitors.
Reviews in Urology
|September 21, 2006
Summary
Finasteride effectively reduces prostate size and prostate-specific antigen (PSA) levels in men with benign prostatic hyperplasia (BPH). While symptom improvement is modest, it offers sustained benefits with minimal side effects, reducing BPH-related surgeries and urinary retention.
Area of Science:
- Urology
- Pharmacology
- Andrology
Background:
- Benign prostatic hyperplasia (BPH) is a common condition in aging men.
- Dihydrotestosterone (DHT) plays a key role in prostate growth.
- 5-alpha-reductase inhibitors are a therapeutic class targeting DHT production.
Purpose of the Study:
- To evaluate the efficacy of finasteride in managing benign prostatic hyperplasia (BPH).
- To assess finasteride's impact on prostate volume, BPH symptoms, and prostate-specific antigen (PSA) levels.
- To analyze the safety profile and clinical outcomes of finasteride therapy for BPH.
Main Methods:
- Review of randomized clinical trials on finasteride for BPH.
- Analysis of effects on prostate size, urinary symptoms, and PSA.
- Comparison with invasive treatment modalities and placebo.
Main Results:
- Finasteride significantly reduces prostate volume and PSA levels.
- Symptomatic improvement is modest compared to invasive treatments.
- Therapy leads to sustained reductions in prostatic volume and PSA.
- Minimal adverse effects observed with finasteride treatment.
- Reduced incidence of BPH-related surgeries and acute urinary retention.
Conclusions:
- Finasteride is an effective medical therapy for reducing prostate size and PSA in BPH.
- It offers sustained benefits with a favorable safety profile.
- Further research is needed to optimize medical management of BPH.
Related Concept Videos
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
01:27Phase I Reactions: Reductive Reactions
Phase I biotransformation reductive reactions are chemical processes that modify drugs by introducing or revealing polar functional groups via reduction. Enzymes called reductases catalyze these reactions, playing a pivotal role in drug metabolism by transforming lipophilic drugs into more polar, water-soluble metabolites for easy excretion. An essential type of reductive reaction is the carbonyl group reduction, where aldehydes and ketones are reduced to alcohols. An example is the...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...